VERU News and Press, Veru Inc. From 03/14/23

2023-03-14 16:23:10 ET Despite an FDA decision to reject its experimental oral COVID therapy sabizabulin early this month, Veru ( NASDAQ: VERU ) announced Tuesday it would continue to proceed with its studies targeting infectious diseases, including COVID-19. Citing remark...

2023-03-08 13:47:06 ET Summary Emergency Use Authorization of Veru Inc.'s Sabizabulin for Covid-19 was rejected by the FDA for United States use for now, barring a new study being done for further review at a later time point. Potential remains to still obtain Emergency Use Author...

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Offi...

2023-03-06 12:07:23 ET Summary Veru's stock price has hit highs of >$20 and its market cap valuation risen >$1.5bn based on the promise of COVID therapy Sabizabulin. Last week however the FDA declined to approve the drug, sending Veru stock tumbling >$3 and valuation to ~...

Stocks finished higher again on Friday, adding to gains posted the previous day. The Nasdaq led the major averages higher, surging by about 2%. Among individual stocks, C3.ai ( NYSE: AI ) represented one of the standout gainers, expanding its value by more than a third after the relea...

Gainers: Altamira Therapeutics ( CYTO ) +86% . Bullfrog AI ( BFRG ) +26% . Seer ( SEER ) +25% . Ardelyx ( ARDX ) +23% . Lucy Scientific Discovery ( LSDI ) +16% . Losers: Praxis Precision Medicines ( PRAX ) -55% . Veru (...

Praxis Precision Medicines PRAX -49% after mid-stage data for movement disorder candidate . Veru VERU -34% after Veru COVID respiratory treatment sabizabulin declined authorization by FDA . Cidara Therapeutics ( CDTX ) -17% on launching concurrent but separa...

The US FDA has declined to authorize sabizabulin, Veru's ( NASDAQ: VERU ) treatment for hospitalized adults with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome . Shares are down 26% in after-hours trading. The agency also addresse...

MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that the U.S. Food and Drug Administration (FDA) has declined to grant at ...

Summary Veru Inc. is eyeing emergency use authorization for its COVID-19 drug Sabizabulin, which is currently under FDA review. Veru Inc. shares fell around 20% to a 52-week low after reporting Q1 FY23 results that fell short of analysts' revenue forecasts. Veru's future lies in obt...